Technical Services

ProcessDevelopment

Separation and purification process development for pharmaceutical and fine chemical customers: process optimization, media and column screening, condition exploration and scale-up validation. With an in-house media library, a 50–300 mm DAC equipment line and HPLC / UPLC / GC analytical platforms, we help customers settle on the best purification route in the shortest time.

Technical Services

Process Development

Separation and purification process development for pharmaceutical and fine chemical customers: process optimization, media and column screening, condition exploration and scale-up validation. With an in-house media library, a DAC equipment line (50–300 mm) and a complete analytical platform, we help customers settle on the best purification route in the shortest time.

From reactors and analytical platforms to the DAC preparative line, and on to SEM, elemental analysis and laser particle sizing for characterizing the beads themselves — essentially all the hardware process development needs is in our own hands.

Process Development Services
Separation and Purification Process Development and Optimization
Technical Services
Inquiry

Drawing on years of chromatographic purification experience, our technical team develops separation and purification processes from bench to pilot scale: target molecule property assessment → media and column screening → mobile phase and gradient optimization → balancing yield against purity → scale-up feasibility validation. A complete process package and method validation report are delivered, shortening the customer's development cycle and reducing the cost of trial and error with media.

Process optimization Media and column screening Bench → pilot scale-up Process package and report delivered In-house media library DAC 50–300 mm HPLC / UPLC / GC
Scope
Process optimization, media and column screening
Deliverables
Process parameter package / method validation report
Applicable stage
Bench · pilot · scale-up
Timeline
Confirmed after requirements assessment (delivered in stages)
Media available
In-house stock including Daisogel, SilicaOne, COSMOSIL and PolymerOne
Scale-up equipment
In-house DAC line, 50–300 mm
Analytical platform
A complete set of instruments including HPLC, UPLC and GC
Technical team
A research team plus a peptide synthesis and purification team with hands-on production experience
Why Microwants

Four foundations: our own media, our own equipment, our own analysis, our own team

The real bottleneck in process development is usually not "we cannot think of a method" but "we cannot get the medium, cannot get instrument time, cannot wait for the analysis". All three are in our own hands, so screening does not wait on lead times and scale-up does not depend on borrowed capacity.

6 majorin-house and distributed media families
50–300 mmDAC equipment line
HPLC·UPLC·GCFull analytical platform
Bench → pilotDelivered end to end by one team
Media

An Extensive In-House Media Library

Screening draws directly on stock, with no external purchasing and no time taken out of the customer's schedule, which fundamentally reduces the cost of trial and error with media.

Scale-up

DAC Line, 50–300 mm

Our own dynamic axial compression packing line spans the full range of diameters from bench confirmation to pilot scale-up, so wherever a method stops and wherever it is validated, it happens within the same equipment logic.

Analytics

A Complete Analysis and Characterization Platform

From HPLC to UPLC to GC, purity, impurity profile and residual solvent are all handled in house. Every time a process parameter changes, the analytical result comes back the same day, without waiting on an outside laboratory.

  • HPLC (UV / DAD) — quantifying purity and impurity profile
  • UPLC — high-resolution fast gradient scanning and screening
  • GC — residual solvents and volatile components
  • packing stations and efficiency evaluation, pluschromatography calculators
Team

A Technical Team with Hands-On Production Experience

Projects are taken on jointly by a research team with a long background in chromatographic separation and a peptide synthesis and purification team with real production experience. The proposal does not stay on paper: it can be run in the reactor and its cost can be worked out.

  • Solid-phase peptide synthesis and crude peptide quality diagnosis
  • Designing orthogonal purification routes across RP, IEX and HILIC
  • Impurity localization and its interface withpreparative separation
  • On-site column packing, commissioning and troubleshooting support
Development Workflow

Five steps: from molecular properties to scale-up feasibility

Each step has a defined input, action and output, so the customer sees data at every stage rather than waiting until the end of the project for a single report.

1

Target molecule property assessment

Establish molecular weight, hydrophobicity, isoelectric point and charge distribution, solubility, and the pH and thermal stability windows, and map known impurity sources (synthetic route, deprotection, degradation). This step governs every subsequent choice of chromatographic mode.

Output:a molecular property profile, a preliminary impurity profile hypothesis, and a shortlist of candidate chromatographic modes
2

Media and column screening

Candidate media are drawn straight from the in-house library and screened in parallel at analytical scale: substrate (silica / polymer / cellulose / gel), bonded phase, pore and particle size, endcapping and pH tolerance — compared in one pass rather than tried one at a time.

Output:two or three preferred media, an initial view on resolution and loading, and a record of why the others were excluded
3

Mobile phase and gradient optimization

Conditions are explored around the organic system, buffer and ion-pairing reagent, pH, column temperature, gradient slope and linear velocity, using UPLC to locate the window quickly and HPLC to reproduce and confirm it.

Output:the optimized mobile phase system and gradient table, plus tolerance ranges for the key parameters
4

Balancing yield against purity

Loading is stepped up and the fraction-cutting strategy optimized to define the trade-off between purity, yield and solvent consumption, with the cut points fixed against the customer's actual quality standard rather than chasing maximum purity.

Output:the loading–purity–yield relationship, a recommended operating point and fraction-cutting rules
5

Scale-up feasibility validation

On our own 50–300 mm DAC line, values are calculated and then measured on the principle of constant bed height and linear velocity with cross-sectional area scaling, checking pressure drop, efficiency and batch reproducibility, and identifying scale-up risks with corresponding contingencies.

Output:a scale-up conversion table, an efficiency report, and a risk list with engineering recommendations
Media Library

Media available for immediate use at the screening stage

All the systems below are our own products or ones for which we are master or exclusive distributor, so they are issued from stock during screening with no need to seek quotations upstream. Once the route is fixed, the transition to volume supply or custom bonding is seamless.

Chromatographic modeMedia availableTypically used for
Reversed phase (RP / IP-RP)Daisogel C18 / C8 / C4 / Phenyl、COSMOSIL、SilicaOnePeptides, oligonucleotides, small-molecule API polishing
Polymer reversed phasePolymerOne PS-DVB seriesStrongly acidic or alkaline systems that silica cannot tolerate
Normal phase / flashDaisogel spherical and irregular silica, FLASHONE columnsCrude fractionation of natural products, synthetic intermediates
Ion exchange / affinityJNC Cellufine Cellulose MediaProteins, polysaccharides, biomacromolecules
Gel filtration (SEC)Gel media (dextran / acrylamide based)Desalting, separation of aggregates and small molecules
Residual metal removalCleanM metal scavenger silicaCatalyst residues, ICH Q3D elemental impurities

Screening is not confined to a single mode. For polar compounds, isomers and hard-to-separate impurities, we look first at orthogonal combinations (IEX → RP, RP → SEC) rather than grinding a gradient indefinitely on one column.Pharma & Biopharma Solutions and oligonucleotide solutions sets out a fuller framework for mode selection.

Scale Ladder

DAC line, 50–300 mm: no need to validate the method elsewhere

We operate our own dynamic axial compression line, so everything from bench confirmation to pilot scale-up happens in one system. The table below gives the geometric relationships at each diameter for a 25 cm bed height as an example; the actual bed height is set per project.

Column IDCross-sectional areaBed volume (25 cm)Scale factor vs. 50 mmTypical role
50 mm19.6 cm²≈ 0.49 LBench method confirmation
100 mm78.5 cm²≈ 1.96 LProcess reproduction and initial scale-up
150 mm176.7 cm²≈ 4.42 LPilot batch validation
200 mm314.2 cm²≈ 7.85 L16×Pilot scale-up / small-batch sample supply
300 mm706.9 cm²≈ 17.7 L36×Commercial feasibility validation
Scale-up principle:keep bed height and linear velocity constant, and scale load and flow rate in proportion to cross-sectional area, expressing the gradient in column volumes (CV) rather than minutes. Only then do retention time and resolution stay consistent across diameters. Conversion can be done quickly with theonline calculators.
Common scale-up failure modes:a changed proportion of extra-column volume broadening peaks, insufficient bed consolidation causing channelling, an injection solvent too strong causing breakthrough, and pressure drop exceeding the equipment limit at large diameters. None of these is visible at bench scale; they must be validated on a real DAC column. SeeDAC Packing Problem Diagnosis
Analysis and Characterization

From Molecule to Bead: Two Loops Closed in Parallel

The speed of process development depends on the loop time from changing a parameter to getting a result. We track the purity and impurity profile of the target molecule by HPLC / UPLC / GC while simultaneously tracking bead quality by SEM, elemental analysis and laser particle sizing — both loops closed in house, with no waiting on outside reports.

PlatformRole in process development
HPLC(UV / DAD)Purity quantification, impurity profile tracking, peak purity assessment, method validation (specificity / linearity / repeatability)
UPLCHigh-resolution fast gradient scanning, completing parallel screening across multiple media and systems in a short time
GCResidual solvents, volatile components and confirmation of solvent removal
Packing and efficiency evaluationAssessment of plate number N, asymmetry factor As and reduced plate height h — the column is confirmed acceptable before the process is run
Scanning electron microscopy (SEM)Direct assessment of bead morphology, sphericity, surface pore structure and fracturing
Elemental analyserVerification of bonded phase carbon load, nitrogen and sulfur content, and batch-to-batch consistency
Laser particle sizer (Malvern)D10 / D50 / D90 and span, used to judge how the size distribution affects packing and pressure drop
Bead Characterization

Half of whether a medium performs is written into the bead's own morphology, carbon load and size distribution. These three instruments let us see the medium clearly at the screening stage, rather than looking for the cause after a packing has failed.

Deliverables

What You Receive Is a Reproducible Process, Not a Conclusion

The two deliverables — a process parameter package and a method validation report — are written so that the customer's engineering team can reproduce the process on their own equipment without coming back for details.

Deliverable 01

Process parameter package

  • Recommended medium and column specification (substrate / bonded phase / pore size / particle size)
  • Mobile phase composition, gradient table, flow rate and column temperature
  • Loading, loading solvent and fraction-cutting rules
  • Regeneration, cleaning and storage procedures, with guidance on medium lifetime
  • Scale-up conversion table and recommended parameters for the target diameter
Deliverable 02

Method validation report

  • Screening records and comparison of candidates, including those excluded and why
  • Representative chromatograms with peak assignments
  • Purity / yield / loading relationship data
  • Method robustness and sensitivity analysis for key parameters
  • Efficiency report and scale-up risk list
Information worth providing at the outset:the target molecule's structure or sequence, current crude purity and chromatogram, known hard-to-separate impurities, the target quality standard, expected batch size and existing equipment. The more complete this is, the closer the first proposal will be to something implementable. Confidential material can be covered by an NDA signed beforehand.
When to Use This Service

When it makes sense to hand the process to us

Establishing a purification route for a new molecule

You have only crude material and a quality standard, and need to establish the chromatographic mode, medium and conditions from scratch and obtain a reproducible process quickly.

An existing process costs too much or yields too little

The method runs, but media consumption is high, solvent volumes are large and yield will not improve; the parameters need rebalancing without sacrificing quality.

Works at bench scale, breaks down on scale-up

Well resolved on an analytical column, but tailing, peak stacking and batch variation appear on a preparative or DAC column; the cause has to be found on real equipment.

A hard-to-separate impurity is holding up the project

Isomers, deletion sequences, oxidation or deamidation products with properties close to the main peak, requiring an orthogonal combination of modes or the support ofImpurity Preparation.

FAQ

Six Questions Customers Ask Most Often

Yes. Screening is carried out at analytical scale and consumes very little sample; larger quantities are only needed once loading studies and scale-up validation begin. We suggest supplying a small representative sample first and adding more once the direction is confirmed.
It depends on the complexity of the molecule, the target quality standard and whether scale-up validation is required. We give a staged timetable after the requirements assessment and deliver interim data by stage, so you do not have to wait for completion to see results.
No. The deliverables state the key physical parameters of the medium (substrate, bonded phase, pore size, particle size, carbon load, endcapping, pH tolerance) so that an equivalent can be sourced elsewhere. The value of the in-house library is that screening does not wait on lead times, not that it locks the customer in.
Yes. We can take on Step 5 alone: reproduce the existing method on a 50–300 mm DAC column, check pressure drop, efficiency and peak shape, determine whether the problem lies with the medium, the packing, the loading or the equipment, and propose improvements.
Yes. The team includes peptide synthesis and purification staff with hands-on production experience, familiar with crude peptide impurity profiles (deletion sequences, deamidation, disulfide scrambling, diastereomers) and the corresponding orthogonal purification strategies. For oligonucleotides, see theoligonucleotide technical overview
An NDA can be signed before the project starts. Structural information, process data and samples supplied by the customer are used only for that project, not for any other purpose, and are not disclosed.

A purification problem to solve?

Send us the target molecule and the current bottleneck; our technical team will assess it and propose a development plan